{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:56:40Z","timestamp":1774587400075,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jsps.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T02:15:26Z","timestamp":1646878526000},"page":"508-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review"],"prefix":"10.1007","volume":"30","author":[{"given":"Lina","family":"Kamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suha","family":"Farraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Bahig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameera","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2022.03.002_b0005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model","author":"Abdelnabi","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jsps.2022.03.002_b0010","doi-asserted-by":"crossref","first-page":"103595","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jsps.2022.03.002_b0015","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.jsps.2022.03.002_b0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.jsps.2022.03.002_b0025","doi-asserted-by":"crossref","unstructured":"Bullard, J., Dust, K., Funk, D., Strong, J., Alexander, D., Garnett, L., C, B., A, B., A, H., Z, S., K, D., N, B., Y, L., PG, V.C., G, P., 2020. predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin. Infect. Dis. 71, 2663\u20132666. <https:\/\/doi.org\/10.1093\/CID\/CIAA638>.","DOI":"10.1093\/cid\/ciaa638"},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jsps.2022.03.002_b0035","author":"FDA"},{"key":"10.1016\/j.jsps.2022.03.002_b0040","author":"FDA"},{"key":"10.1016\/j.jsps.2022.03.002_b0045","author":"FDA"},{"key":"10.1016\/j.jsps.2022.03.002_b0050","author":"FDA"},{"key":"10.1016\/j.jsps.2022.03.002_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0060","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jsps.2022.03.002_b0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.jsps.2022.03.002_b0070","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.03.002_b0075","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.03.002_b0080","author":"Hetero"},{"key":"10.1016\/j.jsps.2022.03.002_b0085","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., 2019. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons. <https:\/\/doi.org\/10.1002\/9781119536604>.","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05538-5","article-title":"Accelerated first-in-human clinical trial of EIDD-2801\/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2","volume":"22","author":"Holman","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.jsps.2022.03.002_b0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"48","key":"10.1016\/j.jsps.2022.03.002_b0100","doi-asserted-by":"crossref","first-page":"28115","DOI":"10.1039\/D0CP05297C","article-title":"Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19","volume":"22","author":"Jena","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jsps.2022.03.002_b0105","doi-asserted-by":"crossref","unstructured":"Jonsdottir, H.R., Siegrist, D., Julien, T., Padey, B., Bouveret, M., Terrier, O., Pizzorno, A., Huang, S., Samby, K., Wells, T.N.C., Boda, B., Rosa-Calatrava, M., Engler, O.B., Constant, S., 2022. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. bioRxiv. <https:\/\/doi.org\/10.1101\/2022.01.10.475377>.","DOI":"10.1101\/2022.01.10.475377"},{"key":"10.1016\/j.jsps.2022.03.002_b0110","doi-asserted-by":"crossref","unstructured":"Kabinger, F., Stiller, C., Schmitzov\u00e1, J., Dienemann, C., Hillen, H.S., H\u00f6bartner, C., Cramer, P., 2021. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. bioRxiv 2021.05.11.443555. <https:\/\/doi.org\/10.1101\/2021.05.11.443555>.","DOI":"10.1101\/2021.05.11.443555"},{"key":"10.1016\/j.jsps.2022.03.002_b0120","doi-asserted-by":"crossref","unstructured":"Khoo, S.H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., Downs, N., Walker, L., Tansley-Hancock, O., Greenhalf, W., Woods, C., Reynolds, H., Marwood, E., Mozgunov, P., Adams, E., Bullock, K., Holman, W., Bula, M.D., Gibney, J.L., Saunders, G., Corkhill, A., Hale, C., Thorne, K., Chiong, J., Condie, S., Pertinez, H., Painter, W., Wrixon, E., Johnson, L., Yeats, S., Mallard, K., Radford, M., Fines, K., Shaw, V., Owen, A., Lalloo, D.G., Jacobs, M., Griffiths, G., 2021. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J. Antimicrob. Chemother. 76, 3286. <https:\/\/doi.org\/10.1093\/JAC\/DKAB318>.","DOI":"10.1093\/jac\/dkab318"},{"key":"10.1016\/j.jsps.2022.03.002_b0125","doi-asserted-by":"crossref","unstructured":"Lan, S., Tedbury, P.R., Ong, Y.T., Shah, R., Slack, R.L., Cilento, M.E., Zhang, H., Du, H., Lulkin, N., Le, U., Kirby, K.A., Melcak, I., Cantara, W.A., Boggs, E.A., Sarafianos, S.G., 2021. Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication. bioRxiv. <https:\/\/doi.org\/10.1101\/2021.12.29.474471>.","DOI":"10.1101\/2021.12.29.474471"},{"key":"10.1016\/j.jsps.2022.03.002_b0130","doi-asserted-by":"crossref","unstructured":"Lieber, C.M., Cox, R.M., Sourimant, J., Wolf, J.D., Juergens, K., Phung, Q., Saindane, M.T., Natchus, M.G., Painter, G.R., Sakamoto, K., Greninger, A.L., Plemper, R.K., 2022. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19. bioRxiv. <https:\/\/doi.org\/10.1101\/2022.02.04.479171>.","DOI":"10.1101\/2022.02.04.479171"},{"issue":"6","key":"10.1016\/j.jsps.2022.03.002_b0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jsps.2022.03.002_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5603\/ARM.a2021.0036","article-title":"Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study","volume":"89","author":"Mahendra","year":"2021","journal-title":"Adv. Respir. Med."},{"issue":"6","key":"10.1016\/j.jsps.2022.03.002_b0145","first-page":"979","article-title":"Electron donor-acceptor capacity of selected pharmaceuticals against COVID-19","volume":"10","author":"Mart\u00ednez","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"12","key":"10.1016\/j.jsps.2022.03.002_b0150","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsps.2022.03.002_b0155","author":"Institute"},{"key":"10.1016\/j.jsps.2022.03.002_b0160","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jsps.2022.03.002_b0165","author":"Nih"},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0170","doi-asserted-by":"crossref","first-page":"101992","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jsps.2022.03.002_b0175","doi-asserted-by":"crossref","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.jsps.2022.03.002_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.jsps.2022.03.002_b0185","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","article-title":"Development of vaccines and antivirals for combating viral pandemics","volume":"4","author":"Pardi","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jsps.2022.03.002_b0190","doi-asserted-by":"crossref","unstructured":"Prince, T., Donovan-Banfield, I., Goldswain, H., Penrice-Randal, R., Turtle, L., Fletcher, T., Khoo, S., Hiscox, J.A., 2021. Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model. bioRxiv. <https:\/\/doi.org\/10.1101\/2021.11.23.469695>.","DOI":"10.1101\/2021.11.23.469695"},{"key":"10.1016\/j.jsps.2022.03.002_b0195","doi-asserted-by":"crossref","unstructured":"Rosales, R., McGovern, B.L., Rodriguez, M.L., Rai, D.K., Cardin, R.D., Anderson, A.S., study group, P.S.P., Sordillo, E.M., van Bakel, H., Simon, V., Garc\\\u2019\\ia-Sastre, A., White, K.M., 2022. Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant. bioRxiv. https:\/\/doi.org\/10.1101\/2022.01.17.476685.","DOI":"10.1101\/2022.01.17.476685"},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat. Commun."},{"issue":"541","key":"10.1016\/j.jsps.2022.03.002_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jsps.2022.03.002_b0210","unstructured":"The Medicines Patent Pool, 2022. 27 generic manufacturers sign agreements with MPP to produce low-cost versions of molnupiravir [WWW Document]. <https:\/\/medicinespatentpool.org\/news-publications-post\/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir> (Accessed 2.28.22)."},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20568-4","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)","volume":"12","author":"Van Kampen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsps.2022.03.002_b0215","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res."},{"issue":"7850","key":"10.1016\/j.jsps.2022.03.002_b0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jsps.2022.03.002_b0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/bmjspcare-2020-002554","article-title":"Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"10.1016\/j.jsps.2022.03.002_b0230","article-title":"Combination of antiviral drugs to inhibit SARS-CoV-2 polymerase and exonuclease as potential COVID-19 therapeutics","author":"Wang","year":"2021","journal-title":"bioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.jsps.2022.03.002_b0235","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 \u2014 interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7809","key":"10.1016\/j.jsps.2022.03.002_b0240","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jsps.2022.03.002_b0245","unstructured":"Worldometer, 2022. COVID Live \u2013 Coronavirus Statistics \u2013 Worldometer [WWW Document]. <https:\/\/www.worldometers.info\/coronavirus\/> (Accessed 2.27.22)."},{"key":"10.1016\/j.jsps.2022.03.002_b0250","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N 4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jsps.2022.03.002_b0255","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:27:51Z","timestamp":1736184471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016422000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1319016422000615"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.03.002","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}